Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
3
60%
Ph phase_3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

terminated120%
unknown120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

NCT02240238
terminatedphase_1

Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

NCT02817113
unknownphase_2

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

NCT03771820
completedphase_3

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

NCT02043288
completedphase_1

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03109158

Clinical Trials (5)

Showing 5 of 5 trials
NCT02240238Phase 1

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

Completed
NCT02817113Phase 1

Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

Terminated
NCT03771820Phase 2

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Unknown
NCT02043288Phase 3

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Completed
NCT03109158Phase 1

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5